Calidi Biotherapeutics Innovates with Genetic Medicines for Cancer Treatment
July 9th, 2025 2:05 PM
By: Newsworthy Staff
Calidi Biotherapeutics Inc. is pioneering a next-generation platform to deliver genetic medicines directly to tumors, offering new hope for hard-to-treat cancers and potentially transforming cancer treatment landscapes.
Calidi Biotherapeutics Inc. (NYSE American: CLDI) is addressing the urgent need for more effective cancer treatments with its innovative platform designed to deliver genetic medicines directly to both primary and metastatic tumors. With cancer diagnoses projected to rise significantly by 2050, the company's approach using engineered viruses to transport therapeutic payloads precisely to tumors could mark a turning point in oncology. Beyond cancer, Calidi is exploring applications in autoimmune disorders, positioning itself alongside leading biotech innovators. This development is crucial as it opens new avenues for treating cancers that have been resistant to current therapies, potentially saving millions of lives worldwide.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
